Curanex Pharmaceuticals closed at $6.19 on Nov 3, up 5.81%, 94.3% below its 52-week closing high. Volume of 11.0K shares was 0.49× its 20-day average (below normal).
Split-adjusted performance: +24.8% over one month, -14.7% over six months.
Short interest was 5.2K shares at the Oct 15 settlement, up 68.5% from the prior report (0.1% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CURXCuranex Pharmaceuticals | $6.19 | +5.81% | −14.7% | — | — | — | $9.7M | |
| BFRGBullfrog AI Holdings | $0.5232 | +5.40% | −27.5% | +547.6% | −636.8% | — | $9.7M | Compare |
| GTBPGT Biopharma | $5.27 | +2.73% | −44.5% | — | — | — | $9.5M | Compare |
| CALCCalciMedica | $1.47 | +5.00% | −51.1% | — | — | — | $10.0M | Compare |
| TPSTTempest Therapeutics | $0.4686 | −0.72% | −78.2% | — | — | — | $9.4M | Compare |
| PTNPalatin Technologies | $5.22 | +4.61% | −73.9% | — | −1449.1% | — | $9.3M | Compare |
| ASBPAspire-Lakewood Holdings | $7.27 | −0.41% | +21.2% | — | −2009.6% | — | $10.2M | Compare |
| INMInMed Pharmaceuticals | $1.68 | +3.07% | +127.0% | — | — | — | $9.2M | Compare |
| LTRNLantern Pharma | $0.6023 | −5.89% | −72.1% | — | — | — | $9.0M | Compare |
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
